Actelion – Innovative products for pulmonary arterial hypertension
J&J acquired Actellion
Actelion has established a leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH). Actelion went public on the Swiss Stock Exchange in 2000.
Industry
Therapeutics
Case facts
Location
Switzerland
Status
Exit March 2001
